Allergy Therapeutics plc (AGY) Earns “Buy” Rating from FinnCap
FinnCap reaffirmed their buy rating on shares of Allergy Therapeutics plc (LON:AGY) in a research note issued to investors on Thursday. FinnCap currently has a GBX 43 ($0.53) price objective on the stock.
Other research analysts also recently issued research reports about the stock. Panmure Gordon reiterated a buy rating and set a GBX 53 ($0.65) price target on shares of Allergy Therapeutics plc in a research report on Tuesday, February 14th. Stifel Nicolaus reiterated a buy rating and set a GBX 60 ($0.74) price target on shares of Allergy Therapeutics plc in a research report on Tuesday, February 14th. Finally, Numis Securities Ltd reiterated a buy rating and set a GBX 37 ($0.46) price target on shares of Allergy Therapeutics plc in a research report on Thursday, January 19th.
Allergy Therapeutics plc (LON:AGY) opened at 27.00 on Thursday. The stock’s market capitalization is GBX 159.07 million. Allergy Therapeutics plc has a 52-week low of GBX 17.25 and a 52-week high of GBX 29.00. The stock has a 50 day moving average of GBX 26.23 and a 200 day moving average of GBX 22.55.
Your IP Address:
About Allergy Therapeutics plc
Allergy Therapeutics Plc is a pharmaceutical company. The Company focuses on the treatment and prevention of allergy with aluminum-free products. The Company’s segments are Central Europe, which includes segments, such as Germany, Australia, Switzerland and the Netherlands; Southern Europe, which includes Italy and Spain; the United Kingdom, and Rest of World.
Receive News & Ratings for Allergy Therapeutics plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics plc and related companies with MarketBeat.com's FREE daily email newsletter.